References
- HSU C., HUTT E., BLOOMFIELD DM., GAILANI D., WEITZ JI. – “Factor XI inhibitor to uncouple thrombosis from hemostasis: JACC review topic of the week” – J Am Coll Cardiol 2021, 78: 625-31
- EMSLEY J., McEWAN P.A., GAILANI D. – “Structure and function of Factor XI” – Blood 2010, 115: 2569-2577
- MOHAMMED BM., MATAFANOV A., IVANOV I., SUN MF., CHENG Q, DICKESON SK. et al – “An update on factor XI structure and function” – Thromb Res 2018, 161: 94-105
- PUY C., RIGG R.A., McCARTY O.J.T. – “The hemostatic role of Factor XI” – Thromb Res 2016, 141: S8-S11
- BOUMA BN., MEIJERS JC. “Role of blood coagulation factor XI in downregulation of fibrinolysis” – Current Opinion in Hematology 2020, 7(5): 266-272
- REITSMA SE., PANG J., RAGHUNATHAN V., SHATZEL JJ., LORENTZ CU., TUCKER EI, et al. – “Role of platelets in regulating activated coagulation Factor XI activity” – Am J Physiol Cell Physiol 2021, 320(3): C365-C374
- DUGA S, SALOMON O. – “Congenital Factor XI deficiency; an update” – Sem Thromb Hemost 2013, 39: 621-631
- LEWANDOWSKA MD, CONNORS J.M. – “Factor XI deficiency” – Hematol/Oncology Clinic 2021, 35(6): 1157-1169
- ZANG X., LEWANDOWSKA M., ALDRIGE M. – “Global epidemiology of factor XI deficiency” – Haemofilia 2023, 29(2): 423-434
- PREIS M., HIRSCH J., KOTLER A., et al. – “Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events” – Blood 2017, 129(09): 1210-1215
- SALOMON O., STEINBERG D.M., KOREN-MORAG N., TANNE D., SELIGSOHN U. – “Reduce incidence of ischaemic stroke in patients with severe factor XI deficiency” – Blood 2008, 111(8): 4113-17
- WHEELER A.P, GAILANI D. – “Why factor XI deficiency is a clinical concern” – Expert Rev Hemat 2016, 9: 629-637
- DE CATERINA R., PRISCO D., EIKELBOOM J.W. – “Factor XI inhibitors: cardiovascular perspectives” – Eur Heart J 2023, 44(4): 280-292
- LING G., KAGDI H., SUBEL B., CHOWDARY P., GOMEZ K. – “Safety and efficacy of factor XI concentrate use in patients with FXI deficiency” – Haemophilia 2016, 22: 411
- MEIJERS JC., TEKELENBURG WL., BOUMA B.N., BERTINA R.M., ROSENDAAL F.R. – “High levels of coagulations Factor XI as a risk factor for venous thrombosis” – N Engl J Med 2000, 342(10): 696
- YANG D.T., FLANDERS M.M., KIM H., RODGERS G.M. – “Elevated factor XI activity levels are associated with an increased odds ratio for cerebrovascular events” – Am J Clin Pathol 2006, 126: 411
- SALOMON O., STEINBERG D.M., ZUCKER M., VARON D., ZIVELIN A., SELIGSOHN U. – “Patients with severe FXI deficiency have a reduce incidence of deep-vein thrombosis” – Thromb Haemost 2011, 105: 769-273
- SHARMAN MOSER S., CHODICK G., NI Y.G., CHALOTHORN D., WANG M.D., SHULDINER A.R., et al. – “The association beetween Factor XI deficiency and risk of bleeding, cardiovascular and venous thromboembolic events” – Thromb Haemost 2022, 122(5): 808-817
- LOWENBERG E.C., MEIJERS J.C., MONIA B.P., LEVI M.– “Coagulation factor XI as a novel target for antithrombotic therapy” – J Thromb Haemost 2010, 8(11): 2349-57
- FREDENBURGH J.S., WEITZ J.I. – “Factor XI as a target for new anticoagulants” – Hamostaseologie 2021, 41(02): 104-110
- BULLER H.R., BETHUNE C., BHANOT S., GAILANI D., MONIA B.P., RASKOB G.E., et al. – “Factor XI antisense oligonucleotide for prevention of venous thrombosis” – N Engl J Med 2015, 372(3): 232-240
- HARRINGTON J., PICCINI J.P., ALEXANDER J.H., GRANGER C.B., PATEL M.R.– “Clinical evaluation of Factor XI Inhibitor Drugs: JACC Review Topic of the Week” – J Am Coll Cardiol 2023, 81(8): 771-779
- GRECO A., LAUDANI C., SPAGNOLO M., AGNELLO F., FARO D.C., FINOCCHIARO S., et al. – “Pharmacology and Clinical Development of Factor XI Inhibitors” – Circulation 2023, 147: 897-913
- VERHAMME P., YI B.A., SEGERS A., SALTER J., BLOOMFIELD D., BULLER H.R., et al. – “Abelacimab for prevention of venous thromboembolism” – N Engl J Med 2021, 387: 609-17
- WEITZ J.I., STRONY J., AGENO W., GAILANI D., HYLEK E.M., LASSEN M.R., et. al. - “Milvexian for the Prevention of Venous Thromboembolism” - N Engl J Med. 2021 Dec 2;385(23):2161-2172.
- PICCINI J.P., CASO V., CONNOLLY S.J., FOX K.A.A., OLDGREN J., JONES W.S., et. al. - “Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study” - Lancet. 2022 Apr 9;399(10333):1383-1390.
- SHOAMANESH A., MUNDL H., SMITH E.E., MASJUAN J., MILANOV I., HIRANO T., et al. – for PACIFIC Stroke investigators “Factor XIa inhibition with asundexian after acute noncardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomized, double-blend, placebo-controlled, phase 2b Trial” – Lancet 2022, 400: 997-1007
- RAO S.V., KIRSCH B., BHATT D.L., BUDAJ A., COPPOLECCHIA R., EIKELBOOM J., et al. – “A multicenter, phase 2, randomized, placebo-controlled double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction” – Circulation 2022, 146: 1196-1206
- GALLI M., LABORANTE R., ORTEGA-PAZ L., FRANCHI F., ROLLINI F., D’AMARIO D., et al. – “Factor XI inhibitors in early clinical trials: a meta-analysis” – Throm Haemost 2023, 123: 576-584
- BRAUNWALD E. – “Inhibitors of F XI: game changers of anti-thrombotic therapy?” – Eur Heart J 2023, 44: 1018-1019
- WANG TF., KHORANA AA., AGNELLI G., BLOOMFIELD D., BONACA MP., BULLER HR., et al. – “Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction” – Oncologist. 2023 Jul 5;28(7):555-564.
- https://www.bayer.com/media/en-us/oceanic-af-study-stopped-early-due-to-lack-of-efficacy/ (date of accession: 15.12.2023).